Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Nebulized BromAc in COVID-19
NCT05258682Phase 2Unknown
- Sponsor
- Mucpharm
- Start
- May 2022
- Primary completion
- Sep 2022
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
01
Overview
A Phase 2 trial of BromAc in coronavirus disease 2019 (COVID-19), sponsored by Mucpharm. Status: unknown.
02
Drugs
BromAc
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05258682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05258682.